News | April 02, 2026
Lupin completes acquisition of VISUfarma
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
The move represents a significant milestone in Lupin’s strategy to expand its specialty care portfolio and strengthen its presence in Europe
Benzonatate is a non-narcotic antitussive that numbs stretch receptors in the respiratory tract
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Enthral.ai’s platform integrates AI-driven capabilities with compliance-first architecture, enabling automated training workflows
A key milestone in this journey has been the introduction of TREAT Program, a first-of-its-kind clinical initiative introduced in India
Certification by TÜV SÜD Product Service GmbH reinforces the company's commitment to globally benchmarked standards in safety, quality, and performance
Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina
The price revision, effective April 3, 2026, brings the innovator molecule within the reach of a significantly larger patient base across the country
The acquisition brings two commercialized, differentiated medicines—EMPAVELI and SYFOVRE —to Biogen’s growth portfolio
The impact on Phase III trials is particularly significant, as these later-stage studies involve larger, committed patient populations and represent years of investment
Subscribe To Our Newsletter & Stay Updated
